Semin Neurol 2013; 33(04): 313-329
DOI: 10.1055/s-0033-1359319
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Alzheimer's Disease

Carly Oboudiyat
1   Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida
Hilary Glazer
1   Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida
Alon Seifan
2   Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York
Christine Greer
1   Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida
Richard S. Isaacson
3   Department of Neurology, Weill Cornell Medical College, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
14 November 2013 (online)


Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system. Neurodegeneration (including neuronal atrophy and/or loss) are attributed to extraneuronal toxic amyloid oligomers and proteins, intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau, region-specific diminished cerebral glucose metabolism, synaptic dysfunction, and mitochondrial dysfunction. Several of these pathologic changes may occur decades before symptom onset, leaving ample time for implementing prevention strategies that target the earliest stages of the disease. In recent years, a myriad of modifiable and nonmodifiable risk factors have been elucidated. We describe the latest criteria for the diagnosis of AD, including earliest diagnostic stage of preclinical AD, which has the highest potential for research, including diagnosis and disease modification. We discuss both FDA-approved pharmacologic treatments, as well as nonpharmacologic strategies for AD therapeutics, including prevention via evidence-based, low-risk interventions. Genotype is an important consideration in managing patients on the AD continuum, as presence of the APOE ε4 allele may influence response to treatment. We present the most current evidence relating to pharmacogenomics, nutrigenomics, and distinctive nutritional requirements targeted toward AD.

  • References

  • 1 President Obama includes Alzheimer's in State of the Union. Available at: . Accessed August 14, 2013
  • 2 World Health Organization and Alzheimer's Disease International. Dementia: A Public Health Priority. Available at: . Accessed October 9, 2013
  • 3 Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011; 3 (77) sr1
  • 4 Wagner SL, Tanzi RE, Mobley WC, Galasko D. Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Arch Neurol 2012; 69 (10) 1255-1258
  • 5 Sperling RA, Aisen PS, Beckett LA , et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3) 280-292
  • 6 Alzheimer's Association. Alzheimer's Disease Facts and Figures 2013. Available at: . Accessed October 9, 2013
  • 7 Plassman BL, Langa KM, Fisher GG , et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29 (1–2) 125-132
  • 8 James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 2012; 307 (17) 1798-1800
  • 9 Hurd MD, Martorell P, Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 369 (5) 489-490
  • 10 Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men?. Am J Epidemiol 2001; 153 (2) 132-136
  • 11 Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006; 67 (3) 441-445
  • 12 Bennett DA, Wilson RS, Schneider JA , et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59 (2) 198-205
  • 13 Bateman RJ, Aisen PS, De Strooper B , et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011; 3 (1) 1
  • 14 Gatz M, Reynolds CA, Fratiglioni L , et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63 (2) 168-174
  • 15 Corder EH, Saunders AM, Strittmatter WJ , et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261 (5123) 921-923
  • 16 Padilla C, Isaacson RS. Genetics of dementia. Continuum (Minneap Minn) 2011; 17 (2 Neurogenetics) 326-342
  • 17 Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21 (2) 153-160
  • 18 Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64 (2) 277-281
  • 19 Kennelly S, Collins O. Walking the cognitive “minefield” between high and low blood pressure. J Alzheimers Dis 2012; 32 (3) 609-621
  • 20 Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis 2012; 30 (Suppl. 02) S127-S145
  • 21 Steffener J, Stern Y. Exploring the neural basis of cognitive reserve in aging. Biochim Biophys Acta 2012; 1822 (3) 467-473
  • 22 Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3 (6) 343-353
  • 23 Lindwall M, Cimino CR, Gibbons LE , et al. Dynamic associations of change in physical activity and change in cognitive function: coordinated analyses of four longitudinal studies. J Aging Res 2012; 2012: 493598
  • 24 García AM, Ramón-Bou N, Porta M. Isolated and joint effects of tobacco and alcohol consumption on risk of Alzheimer's disease. J Alzheimers Dis 2010; 20 (2) 577-586
  • 25 Johnson VE, Stewart W, Smith DH. Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. Brain Pathol 2012; 22 (2) 142-149
  • 26 Daviglus ML, Plassman BL, Pirzada A , et al. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol 2011; 68 (9) 1185-1190
  • 27 Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker III JC. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131 (2) 162-169
  • 28 Hoffman LB, Schmeidler J, Lesser GT , et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009; 72 (20) 1720-1726
  • 29 Albanese E, Lombardo FL, Prince MJ, Stewart R. Dementia and lower blood pressure in Latin America, India, and China: a 10/66 cross-cohort study. Neurology 2013; 81 (3) 228-235
  • 30 Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke 2012; 43 (11) 3137-3146
  • 31 Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226 (1–2) 71-74
  • 32 Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006; 37 (5) 1165-1170
  • 33 Li NC, Lee A, Whitmer RA , et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465
  • 34 Shlyakhto E. Observational Study on Cognitive Function and Systolic Blood Pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature. Curr Med Res Opin 2007; 23 (Suppl. 05) S13-S18
  • 35 Gao Y, O'Caoimh R, Healy L , et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013; 3 (7) e002881
  • 36 Furiya Y, Ryo M, Kawahara M, Kiriyama T, Morikawa M, Ueno S. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Alzheimers Dement 2013; 9 (5) 512-518
  • 37 Fogari R, Mugellini A, Zoppi A , et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59 (12) 863-868
  • 38 Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 2012; 12 (2) 207-214
  • 39 Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012; 69 (12) 1632-1638
  • 40 Reboussin D. Systolic Blood Pressure Intervention Trial (SPRINT). Winston-Salem, NC: Wake Forest University; 2010
  • 41 Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67 (6) 505-512
  • 42 Burns CM, Chen K, Kaszniak AW , et al. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology 2013; 80 (17) 1557-1564
  • 43 van den Berg E, Dekker JM, Nijpels G , et al. Blood pressure levels in pre-diabetic stages are associated with worse cognitive functioning in patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25 (7) 657-664
  • 44 Peila R, Rodriguez BL, Launer LJ ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51 (4) 1256-1262
  • 45 Gold M, Alderton C, Zvartau-Hind M , et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30 (2) 131-146
  • 46 Harrington C, Sawchak S, Chiang C , et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011; 8 (5) 592-606
  • 47 Tzimopoulou S, Cunningham VJ, Nichols TE , et al. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis 2010; 22 (4) 1241-1256
  • 48 Schwartz R. Pioglitazone or exercise to treat mild cognitive impairment (MCI). Denver, CO: University of Colorado, Denver; 2012
  • 49 Luchsinger JA. Metformin in Amnestic Mild Cognitive Impairment (MCI). New York, NY: Columbia University; 2013
  • 50 Geda YE, Ragossnig M, Roberts LA , et al. Caloric intake, aging, and mild cognitive impairment: a population-based study. J Alzheimers Dis 2013; 34 (2) 501-507
  • 51 Gutierrez J, Isaacson R. Prevention of cognitive decline. In: Ravdin LD, Katzen HL, , eds. Handbook on the Neuropsychology of Aging and Dementia. New York, NY: Springer Science + Business Media, LLC; 2013
  • 52 Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012; 11 (11) 1006-1012
  • 53 Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5 (9) 735-741
  • 54 Llewellyn DJ, Lang IA, Xie J, Huppert FA, Melzer D, Langa KM. Framingham Stroke Risk Profile and poor cognitive function: a population-based study. BMC Neurol 2008; 8: 12
  • 55 Kaffashian S, Dugravot A, Elbaz A , et al. Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores. Neurology 2013; 80 (14) 1300-1306
  • 56 Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol 2010; 67 (7) 835-841
  • 57 Gibson GE, Shi Q. A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J Alzheimers Dis 2010; 20 (Suppl. 02) S591-S607
  • 58 Ittner LM, Götz J. Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12 (2) 65-72
  • 59 Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8 (9) 663-672
  • 60 Reiman EM, Chen K, Alexander GE , et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 2004; 101 (1) 284-289
  • 61 Silva DF, Selfridge JE, Lu J, , e L, Cardoso SM, Swerdlow RH. Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv Pharmacol 2012; 64: 83-126
  • 62 Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010; 47 (2) 183-189
  • 63 Middleton LE, Yaffe K. Targets for the prevention of dementia. J Alzheimers Dis 2010; 20 (3) 915-924
  • 64 Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69 (24) 2197-2204
  • 65 Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66 (2) 200-208
  • 66 Roy M, Nugent S, Tremblay-Mercier J , et al. The ketogenic diet increases brain glucose and ketone uptake in aged rats: a dual tracer PET and volumetric MRI study. Brain Res 2012; 1488: 14-23
  • 67 Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008; 9 (Suppl. 02) S16
  • 68 Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008; 1147: 180-195
  • 69 Cunnane S, Nugent S, Roy M , et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 2011; 27 (1) 3-20
  • 70 Montine TJ, Phelps CH, Beach TG , et al; National Institute on Aging; Alzheimer's Association. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123 (1) 1-11
  • 71 Klunk WE, Engler H, Nordberg A , et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55 (3) 306-319
  • 72 Clark C, Beach T, Coleman E , et al. Correspondence of florbetapir-PET and beta-amyloid pathology: analysis of 59 subjects who came to autopsy. Paper presented at: Human Amyloid Imaging; January 12–13, 2012; Miami, FL. Available at: . Accessed October 9. 2013
  • 73 Buchhave P, Blennow K, Zetterberg H , et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS ONE 2009; 4 (7) e6294
  • 74 Braak H, Rüb U, Schultz C, Del Tredici K. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2006; 9 (3, Suppl) 35-44
  • 75 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7) 939-944
  • 76 McKhann GM, Knopman DS, Chertkow H , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3) 263-269
  • 77 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed). Arlington, VA: American Psychiatric Association; 2013
  • 78 Gifford KA, Liu D, Lu Z , et al. The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. Alzheimers Dement 2013;
  • 79 Prince M, Bryce R, Ferri C. Alzheimer's Disease International: World Alzheimer Report 2011. London, England: Institute of Psychiatry, King's College London; 2011
  • 80 Zola SM, Manzanares CM, Clopton P, Lah JJ, Levey AI. A behavioral task predicts conversion to mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen 2013; 28 (2) 179-184
  • 81 Caselli RJ, Locke DE, Dueck AC , et al. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement 2013;
  • 82 Talbot K, Wang HY, Kazi H , et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122 (4) 1316-1338
  • 83 Frost S, Kanagasingam Y, Sohrabi H , et al; AIBL Research Group. Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transcult Psychiatry 2013; 3: e233
  • 84 Murray IV, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) 2011; 236 (7) 772-782
  • 85 Jack Jr CR, Knopman DS, Jagust WJ , et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12 (2) 207-216
  • 86 Frisoni GB, Bocchetta M, Chételat G , et al; For ISTAART's NeuroImaging Professional Interest Area. Imaging markers for Alzheimer disease: Which vs how. Neurology 2013; 81 (5) 487-500
  • 87 Parra MA, Ascencio LL, Urquina HF, Manes F, Ibáñez AM. P300 and neuropsychological assessment in mild cognitive impairment and Alzheimer dementia. Front Neurol 2012; 3: 172
  • 88 Sheinerman KS, Tsivinsky VG, Crawford F, Mullan MJ, Abdullah L, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany, NY Online) 2012; 4 (9) 590-605
  • 89 Platt B, Welch A, Riedel G. FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease. Biochem Soc Trans 2011; 39 (4) 874-880
  • 90 Podlesniy P, Figueiro-Silva J, Llado A , et al. Low CSF concentration of mitochondrial DNA in preclinical Alzheimer's disease. Ann Neurol 2013;
  • 91 Hu WT, Chen-Plotkin A, Arnold SE , et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010; 119 (6) 669-678
  • 92 Minati L, Grisoli M, Bruzzone MG. MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. J Geriatr Psychiatry Neurol 2007; 20 (1) 3-21
  • 93 Chhatwal JP, Schultz AP, Johnson K , et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology 2013; 81 (8) 736-744
  • 94 Dumurgier J, Mouton-Liger F, Lapalus P , et al; Groupe d'Investigation du Liquide Cephalorachidien (GIL) Study Network. Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS ONE 2013; 8 (1) e53587
  • 95 Buerger K, Ernst A, Ewers M , et al. Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry 2009; 65 (11) 979-984
  • 96 Schipper HM. Biomarker potential of heme oxygenase-1 in Alzheimer's disease and mild cognitive impairment. Biomarkers Med 2007; 1 (3) 375-385
  • 97 Sperling R. Anti-Amyloid Treatment in Asymptomatic AD–The A4 Trial. Available at:
  • 98 Douaud G, Refsum H, de Jager CA , et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 2013; 110 (23) 9523-9528
  • 99 Neafsey EJ, Collins MA. Moderate alcohol consumption and cognitive risk. Neuropsychiatr Dis Treat 2011; 7: 465-484
  • 100 Laske C, Stellos K, Hoffmann N , et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 2011; 14 (3) 399-404
  • 101 Parbery-Clark A, Anderson S, Hittner E, Kraus N. Musical experience offsets age-related delays in neural timing. Neurobiol Aging 2012; 33 (7) e1-e4
  • 102 de Villers-Sidani E, Alzghoul L, Zhou X, Simpson KL, Lin RC, Merzenich MM. Recovery of functional and structural age-related changes in the rat primary auditory cortex with operant training. Proc Natl Acad Sci U S A 2010; 107 (31) 13900-13905
  • 103 Williams JW, Plassman BL, Burke J, Benjamin S. Preventing Alzheimer's disease and cognitive decline. Evidence Reports/Technology Assessments, No. 193. Rockville, MD: Agency for Healthcare Research and Quality; 2010
  • 104 Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66 (2) 216-225
  • 105 Devore EEKJ, Breteler MM, Grodstein F. Dietary intakes of berries and flavinois in relation to cognitive decline. Ann Neurol 2012; 72 (1) 135-143
  • 106 Hanna-Pladdy B, Gajewski B. Recent and past musical activity predicts cognitive aging variability: direct comparison with general lifestyle activities. Front Hum Neurosci 2012; 6: 198
  • 107 Berr C, Akbaraly T, Arnaud J, Hininger I, Roussel AM, Barberger Gateau P. Increased selenium intake in elderly high fish consumers may account for health benefits previously ascribed to omega-3 fatty acids. J Nutr Health Aging 2009; 13 (1) 14-18
  • 108 Kraus N. Biological impact of music and software-based auditory training. J Commun Disord 2012; 45 (6) 403-410
  • 109 Sano M, Egelko S, Donohue M , et al; the Alzheimer Disease Cooperative Study Investigators. Developing Dementia Prevention Trials: Baseline Report of the Home-Based Assessment Study. Alzheimer Dis Assoc Disord 2012;
  • 110 Gardener S, Gu Y, Rainey-Smith SR , et al; AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population. Transcult Psychiatry 2012; 2: e164
  • 111 Gu Y, Luchsinger JA, Stern Y, Scarmeas N. Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease. J Alzheimers Dis 2010; 22 (2) 483-492
  • 112 Tangney CC, Scarmeas N. The good, bad, and ugly? How blood nutrient concentrations may reflect cognitive performance. Neurology 2012; 78 (4) 230-231
  • 113 Kliegel M, Zimprich D, Rott C. Life-long intellectual activities mediate the predictive effect of early education on cognitive impairment in centenarians: a retrospective study. Aging Ment Health 2004; 8 (5) 430-437
  • 114 Reed BR, Dowling M, Tomaszewski Farias S , et al. Cognitive activities during adulthood are more important than education in building reserve. J Int Neuropsychol Soc 2011; 17 (4) 615-624
  • 115 Fritsch T, McClendon MJ, Smyth KA, Lerner AJ, Friedland RP, Larsen JD. Cognitive functioning in healthy aging: the role of reserve and lifestyle factors early in life. Gerontologist 2007; 47 (3) 307-322
  • 116 Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging 2012; 33 (2) e19-e27
  • 117 Desideri G, Kwik-Uribe C, Grassi D , et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension 2012; 60 (3) 794-801
  • 118 Yurko-Mauro K, McCarthy D, Rom D , et al; MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6 (6) 456-464
  • 119 Winblad BGS, Gauthier S, Scinto L , et al; GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70 (22) 2024-2035
  • 120 Pa J, Berry AS, Compagnone M , et al. Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. Ann Neurol 2013; 73 (6) 762-773
  • 121 Gardener H, Scarmeas N, Gu Y , et al. Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study. Arch Neurol 2012; 69 (2) 251-256
  • 122 Jeerakathil T, Wolf PA, Beiser A , et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004; 35 (8) 1857-1861
  • 123 Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT ; Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50 (1) 136-145
  • 124 Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E ; Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57 (4) 613-620
  • 125 Novartis. Exelon Patch Prescribing Information. Available at: . Accessed October 9, 2013
  • 126 Peskind ER, Potkin SG, Pomara N , et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14 (8) 704-715
  • 127 Caplan LR. How well does ‘evidence-based’ medicine help neurologists care for individual patients?. Rev Neurol Dis 2007; 4 (2) 75-84
  • 128 Ringman JM, Frautschy SA, Teng E , et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 2012; 4 (5) 43
  • 129 Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 2008; 23 (2) 155-160
  • 130 Richards M, Sacker A. Lifetime antecedents of cognitive reserve. J Clin Exp Neuropsychol 2003; 25 (5) 614-624
  • 131 Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998; 50 (3) 669-677
  • 132 Bateman RJ, Xiong C, Benzinger TL , et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367 (9) 795-804
  • 133 Poirier JDM, Delisle MC, Quirion R , et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92 (26) 12260-12264
  • 134 Reger MA, Henderson ST, Hale C , et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004; 25 (3) 311-314
  • 135 Gibson GE, Haroutunian V, Zhang H , et al. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol 2000; 48 (3) 297-303
  • 136 Delrieu J, Ousset PJ, Caillaud C, Vellas B. ‘Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 2012; 120 (Suppl. 01) 186-193
  • 137 Patterson CETS, Todd SA, Passmore AP. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenomics J 2011; 11 (6) 444-450
  • 138 Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutri Metab (Lond). 2009; 6: 31–56
  • 139 Quinn JF, Raman R, Thomas RG , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304 (17) 1903-1911
  • 140 Salloway S, Sperling R, Gilman S , et al; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73 (24) 2061-2070
  • 141 Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T , et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63 (10) 1402-1408
  • 142 Roses AD, Saunders AM. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimers Dement 2006; 2 (2) 59-70
  • 143 Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009; 6: 31
  • 144 Henderson ST, Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet 2011; 12: 137
  • 145 Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80 (1) 13-17
  • 146 Li G, Shofer JB, Rhew IC , et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 2010; 58 (7) 1311-1317
  • 147 Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006; 185: 3-7
  • 148 Barberger-Gateau P, Raffaitin C, Letenneur L , et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007; 69 (20) 1921-1930
  • 149 Podewils LJ, Guallar E, Kuller LH , et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005; 161 (7) 639-651